Watch TENX. Know when insiders buy.
One email the day a filing lands. Free.
TENX
TENAX THERAPEUTICS, INC.
1.63
+0.00 +0.00%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
50
WATCH · insiders 100, shorts 0
Insiders, 90 days
+$4.9M
net buying · 11 buys, 0 sells · cluster
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $61MP/E —DIV YIELD —FCF YIELD —REV TTM $0NET INCOME −$64.9MNET CASH —52W 1.36 – 18.32SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$18.8M | −$17.8M | — | -0.35 | −$14.2M | — | — | Jul 31 |
| Q1 2026 · Mar 31 | $0 | — | — | −$16.6M | −$15.7M | — | -0.35 | −$9.3M | — | — | Jul 31 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$16.4M | −$15.5M | — | -0.38 | −$13.4M | — | — | Mar 10 |
| Q3 2025 · Sep 30 | $0 | — | — | −$16.8M | −$15.8M | — | -0.40 | −$9.2M | — | — | Nov 12 |
| Q2 2025 · Jun 30 | $0 | — | — | −$11.8M | −$10.8M | — | -0.27 | −$6.3M | — | — | Jul 31 |
| Q1 2025 · Mar 31 | $0 | — | — | −$11.3M | −$10.4M | — | -0.28 | −$7M | — | — | Jul 31 |
| Q4 2024 · Dec 31derived | — | — | — | −$7.3M | −$6.3M | — | 0.22 | −$3.5M | — | — | Mar 10 |
| Q3 2024 · Sep 30 | — | — | — | −$4.6M | −$4M | −300.9% | -0.19 | −$3.1M | — | — | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$3.7M | −$3.6M | — | -1.83 | −$3M | — | — | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$3.9M | −$3.8M | — | -3.12 | −$5.2M | — | — | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$13.1M | −$12.2M | — | — | −$1.2M | — | — | Mar 25 |
| Q3 2023 · Sep 30 | — | — | — | $2.1M | $2M | — | — | −$2.1M | — | — | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$56.4M | −$52.6M | — | -1.34 | −$35.8M | — | — | — | — |
| FY2024 · to Dec 31 | $0 | — | −$19.5M | −$17.6M | — | -1.15 | −$14.8M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$8.2M | −$7.7M | — | -31.04 | −$5.9M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | $11.1M | $11M | — | — | −$11.4M | $2K | −$11.4M | — | — |
| FY2021 · to Dec 31 | — | — | −$32.7M | −$32.5M | — | -1.58 | −$10.9M | $5K | −$10.9M | — | — |
| FY2020 · to Dec 31 | — | — | $9.9M | −$9.9M | — | -0.95 | −$9.3M | $3K | −$9.3M | — | — |
Every number comes from TENAX THERAPEUTICS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.